Healthequity Inc’s filing revealed that its Director SELANDER ROBERT W unloaded Company’s shares for reported $0.45 million on Apr 09 ’25. In the deal valued at $77.65 per share,5,750 shares were sold. As a result of this transaction, SELANDER ROBERT W now holds 84,969 shares worth roughly $8.74 million.
Then, Stephen Neeleman bought 9,019 shares, generating $720,433 in total proceeds.
Before that, Delano Ladd bought 6,991 shares. Healthequity Inc shares valued at $558,437 were divested by the Officer at a price of $79.88 per share.
A number of analysts have revised their coverage, including Raymond James’s analysts, who increased its forecast for the stock in late March from “an Outperform” to “a Strong buy”. Mizuho began covering HQY with “an Outperform” recommendation on December 04, 2024. Goldman started covering the stock on November 15, 2024. It rated HQY as “a Neutral”.
Price Performance Review of HQY
On Monday, Healthequity Inc [NASDAQ:HQY] saw its stock jump 2.19% to $102.81. Over the last five days, the stock has gained 3.84%. Healthequity Inc shares have risen nearly 7.15% since the year began. Nevertheless, the stocks have risen 31.15% over the past one year. While a 52-week high of $115.59 was reached on 02/13/25, a 52-week low of $65.01 was recorded on 04/07/25. SMA at 50 days reached $89.90, while 200 days put it at $92.70.
Levels Of Support And Resistance For HQY Stock
The 24-hour chart illustrates a support level at 99.94, which if violated will result in even more drops to 97.07. On the upside, there is a resistance level at 104.58. A further resistance level may holdings at 106.34. The Relative Strength Index (RSI) on the 14-day chart is 67.01, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.85, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 7.28%. Stochastics %K at 82.85% indicates the stock is a selling.
The most recent change occurred on April 04, 2024 when JMP Securities began covering the stock and recommended ‘”a Mkt outperform”‘ rating along with a $101 price target.
